Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
43.19
+0.20 (0.47%)
At close: Mar 28, 2025, 4:00 PM
44.47
+1.28 (2.97%)
After-hours: Mar 28, 2025, 5:20 PM EDT
Cytokinetics Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Cytokinetics stock have an average target of 82, with a low estimate of 60 and a high estimate of 120. The average target predicts an increase of 89.86% from the current stock price of 43.19.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 28, 2025.
Analyst Ratings
The average analyst rating for Cytokinetics stock from 17 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 5 | 6 | 6 |
| Buy | 6 | 8 | 8 | 8 | 9 | 9 |
| Hold | 4 | 4 | 4 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 16 | 16 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +177.84% | Feb 28, 2025 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $70 → $67 | Hold → Buy | Upgrades | $70 → $67 | +55.13% | Feb 13, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $86 | Strong Buy | Initiates | $86 | +99.12% | Feb 7, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $78 | Buy | Reiterates | $78 | +80.60% | Feb 7, 2025 |
| Needham | Needham | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +66.71% | Feb 6, 2025 |
Financial Forecast
Revenue This Year
51.04M
from 18.47M
Increased by 176.28%
Revenue Next Year
235.72M
from 51.04M
Increased by 361.83%
EPS This Year
-5.43
from -5.26
EPS Next Year
-4.27
from -5.43
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 172.8M | 420.0M | 974.3M | ||
| Avg | 51.0M | 235.7M | 564.4M | ||
| Low | 6.4M | 109.3M | 303.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 835.5% | 722.9% | 313.3% | ||
| Avg | 176.3% | 361.8% | 139.5% | ||
| Low | -65.5% | 114.0% | 28.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.04 | -2.63 | 1.21 | ||
| Avg | -5.43 | -4.27 | -1.00 | ||
| Low | -6.69 | -6.38 | -5.02 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.